SCHEMBL25899200

SCHEMBL25899200

CC(C)(C)Cn1cnc2cc(C(C)(C)C)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.43
FDPS P14324 1/20 0.41
MAPT P10636 2/20 0.41
HSD17B10 Q99714 2/20 0.41
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HPGD P15428 2/20 0.36
PI4KA P42356 1/20 0.36
PI4K2B Q8TCG2 1/20 0.36
PI4K2A Q9BTU6 1/20 0.36
PI4KB Q9UBF8 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26803323 0.88 NR1I2 (0.41) NR1I2FDPSMAPTHSD17B10NPC1
SCHEMBL12873184 0.85 NPC1 (0.49) NR1I2MAPTHSD17B10NPC1RAB9A
SCHEMBL15828632 0.83 NPC1 (0.49) NR1I2MAPTHSD17B10NPC1RAB9A
SCHEMBL23479575 0.81 TDP1 (0.49) NR1I2FDPSMAPTHSD17B10NPC1
SCHEMBL14501874 0.81 POLB (0.56) NR1I2FDPSMAPTHSD17B10NPC1
SCHEMBL15828631 0.81 MAPT (0.49) NR1I2MAPTHSD17B10NPC1RAB9A
SCHEMBL15829318 0.79 MAPT (0.43) NR1I2MAPTHSD17B10NPC1RAB9A
SCHEMBL21026261 0.79 GABRG2 (0.44) NR1I2MAPTHSD17B10MEN1KMT2A
SCHEMBL23347479 0.78 NR1I2 (0.36) NR1I2FDPSMAPTHSD17B10NPC1
SCHEMBL21026260 0.77 MAPT (0.48) NR1I2MAPTHSD17B10GAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, FCGR3B, FCGR2A NR1I2 2593/4885FDPS 4755/4885MAPT 3491/4885
US-20230279426-A1 MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, ASGR1, FCGR3B NR1I2 2185/4885FDPS 4830/4885MAPT 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.